Promising new combo targets tough stomach cancer
NCT ID NCT05980481
First seen Oct 31, 2025 · Last updated May 16, 2026 · Updated 31 times
Summary
This study tests a new drug combination (RC48-ADC plus toripalimab and either chemotherapy or trastuzumab) as a first treatment for advanced stomach cancer that has spread. About 201 adults with or without a specific protein (HER2) will participate. The goal is to see if the combo can shrink tumors and slow the cancer's growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.